Compare Enveric Biosciences Inc (ENVB) vs United Microelectronics Corp (UMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs United Microelectronics Corp — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.69M), while United Microelectronics Corp trades at $22.91 (market cap $58.02B). The key difference: United Microelectronics Corp is far larger — about 8672.6× Enveric Biosciences Inc's market cap, and United Microelectronics Corp pays a 1.76% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and United Microelectronics Corp for 42 Days on average.
| ENVB | UMC | |
|---|---|---|
Market Cap | $6.69M | $58.02B |
Volume | 41,141 | 11,897,809 |
Sector | Health | Technology |
52-Week High | $10.80 | $28.02 |
52-Week Low | $1.27 | $7.02 |
Typical Hold Time | 14 Days | 42 Days |
Enterprise Value | -$1.60M | $55.10B |
Dividend Yield | — | 1.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
United Microelectronics (UMC) trades at $23.31, up 0.52% with a bullish technical signal despite mixed moving averages. The company shows strong profitability with 32.75% net income margin and 21.03% ROE, though revenue growth has slowed from 2022 peaks. Recent earnings beats and positive 2026 projections suggest operational strength, while analyst consensus remains cautious with 53% hold ratings.
UMC presents a mixed outlook with strong fundamentals offset by valuation concerns. The stock's 250% annual gain creates near-term resistance, while projected 2026 earnings growth of 103% offers upside potential. Key risks include semiconductor cyclicality and AI spending volatility, requiring careful position sizing despite intrinsic value estimates near $29.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About United Microelectronics Corp
Founded in 1980, United Microelectronics is the world's third-largest dedicated chip foundry, with 7% market share in 2021, according to Gartner, after TSMC and GlobalFoundries. UMC's headquarters are in Hsinchu, Taiwan, and it operates 12 fabs in Taiwan, Mainland China, Japan and Singapore, with additional sales offices in Europe, the U.S. and South Korea. UMC features a diverse customer base including Texas Instruments, MediaTek, Qualcomm, Broadcom, Xilinx and Realtek, supplying a wide range of products applied in communications, display, memory, automotive and more. UMC employs about 20,000 people.
Read more on UMC →
